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Abstract 
Background: It is encouraging to see a substantial increase in individuals surviving cancer. Even more so since most 
of them will have a positive effect on society by returning to work. However, many cancer survivors have unmet 
needs, especially when it comes to improving their quality of life (QoL). Only few survivors are able to meet all of the 
recommendations regarding well‑being and there is a body of evidence that cancer survivors’ needs often remain 
neglected from health policy and national cancer control plans. This increases the impact of inequalities in cancer 
care and adds a dangerous component to it. The inequalities affect the individual survivor, their career, along with 
their relatives and society as a whole. The current study will evaluate the impact of the use of big data analytics and 
artificial intelligence on the self‑efficacy of participants following intervention supported by digital tools. The second‑
ary endpoints include evaluation of the impact of patient trajectories (from retrospective data) and patient gathered 
health data on prediction and improved intervention against possible secondary disease or negative outcomes (e.g. 
late toxicities, fatal events).
Methods/design: The study is designed as a single‑case experimental prospective study where each individual 
serves as its own control group with basal measurements obtained at the recruitment and subsequent measure‑
ments performed every 6 months during follow ups. The measurement will involve CASE‑cancer, Patient Activation 
Measure and System Usability Scale. The study will involve 160 survivors (80 survivors of Breast Cancer and 80 survi‑
vors of Colorectal Cancer) from four countries, Belgium, Latvia, Slovenia, and Spain. The intervention will be imple‑
mented via a digital tool (mHealthApplication), collecting objective biomarkers (vital signs) and subjective biomarkers 
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Background
Cancer is the second cause of mortality worldwide, with 
18 million new cases in 2018 and 9.5 million deaths [1, 2]. 
A significant increase of new cases is expected in the next 
20 to 40 years. In 2018, 3.91 million new cases of cancer 
(excluding non-melanoma skin cancer) were estimated in 
Europe [3], including approximately 1.6 million patients 
of working age [4, 5]. The most common cancer sites were 
breast (523,000 cases), followed by colorectum (500,000) 
[3]. The numbers of cancer surviors are increasing due 
to advances in cancer treatment and early detection are. 
In the EUROCARE study [6], the 1999–2007 European 
mean age-standardized 5-year relative survival for breast 
cancer (women only) was 81.8% (95% CI 81.6–82.0). For 
colorectal cancer, the European mean age-standardized 
5-year survival was 57.0% (95% CI 56.8–57.3). More than 
half of the European cancer patients survive 5 years or 
longer after diagnosis leading to more cancer survivors 
who experience long-term or latent side effects as a result 
of cancer treatments [6].
It is very encouraging to see substantially more people 
surviving cancer, especially as many of them will have 
a positive effect on society. However, many cancer sur-
vivors have unmet needs, especially when it comes to 
improving the quality of life (QoL), in addition to length-
ening of life span [7]. Study in [8] showed that approxi-
mately one in four survivors face moderate to severe 
physical or psychological issues after their cancer treat-
ment. Some cancer survivors have levels of fatigue three-
fold greater than the general population [9], and many 
carry a life-long fear of cancer recurrence [10]. Cancer 
survivors from vulnerable populations or with a low-
socioeconomic status are particularly at risk of having 
QoL lower as compared to the general population [11]. 
Returning to work had been observed as difficult for a 
significant number of survivors, A survey in [12] reports 
that over one-third of employers highlighted concerns 
about workplace discrimination against cancer survivors.
Fear of cancer recurrence, late toxicity limitations, 
comorbidities, nutritional disorders and high levels of 
psychological distress and depression, including the risk 
of suicide, are generally not appropriately assessed in 
the guidelines’ recommendations used in follow-up after 
treatment. However, scientific publications in recent 
years reflect the growing interest in evaluating and pre-
venting these and other problems to improve the quality 
of life of cancer survivors.
In the last decades, evidence is emerging that lifestyle 
of cancer survivors positively influence cancer prog-
nosis as for example, exercise [13], increased fruit and 
vegetable consumption, healthy body weight and body 
composition [14], smoking cessation [15], and cognitive 
behavioral therapy [9]. However, only few survivors can 
follow all of these recommendations [15]. There is sig-
nificant research highlighting how the health policy and 
national cancer plans often neglected cancer survivors’ 
actual needs [16]. Furthermore, the increasing number of 
cancer survivors is likely to have a substantial economic 
impact on the health system.
The PERSIST European Project: "Patients-centered 
SurvivorShIp care plan after Cancer treatments based 
on Big Data and Artificial Intelligence technologies", was 
developed to improve health outcomes, QoL and pro-
mote stress reduction related to breast and colorectal 
cancer survivors, who have gone beyond curative cancer 
treatment. The choice of these two cancers was based on 
their relatively high incidence and survival rates, consti-
tuting a large number of survivors whose follow-up can 
be improved.
PERSIST consortium aims at developing an open and 
interoperable ecosystem to improve the care of cancer 
survivors. In the project, we expect to achieve increased 
self-efficacy and satisfaction with care. We also foresee a 
reduction in psychological distress due to better manage-
ment of the consequences of cancer and treatment. Com-
pared to usual care, PERSIST interventions are expected 
to (1) improve health and well-being and, where applica-
ble, contribute to faster reintegration into the labor mar-
ket, (2) to increase the effectiveness of cancer treatment 
and follow-up by supporting the decision-making with 
prediction models, trained on Big Data (3) contribute 
to more optimal treatment decisions that will reflect in 
(PROs) with the support of a (embodied) conversational agent. Additionally, the Clinical Decision Support system 
(CDSS), including visualization of cohorts and trajectories will enable oncologists to personalize treatment for an effi‑
cient care plan and follow‑up management.
Discussion: We expect that cancer survivors will significantly increase their self‑efficacy following the personalized 
intervention supported by the m‑HealthApplication compared to control measurements at recruitment. We expect to 
observe improvement in healthy habits, disease self‑management and self‑perceived QoL.
Trial registration ISRCTN97617326. https:// doi. org/ 10. 1186/ ISRCT N9761 7326. Original Registration Date: 26/03/2021.
Keywords: Cancer survivors, Well‑being, Quality of life, Single‑case experimental prospective study, Digital 
intervention, Artificial intelligence, Health application, Conversational agent
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positive (HR)QoL outcomes of survivors, and (4) improve 
information and evidence to increase the efficacy of man-
agement, intervention and prevention policies targeting 
timely treatment of side effects and, if possible, avoidance 
of secondary diseases and fatal events.
Several studies have shown how patients and survi-
vors can benefit from digital tools and specifically, solu-
tions that capture patient-reported outcomes (PROs) 
[17, 18] or solutions that capture patient gathered health 
data [19]. Nevertheless, the integration of digital tools 
in clinical settings still raises several different ques-
tions. The clinical study is specifically contemplated to 
assess the efficacy of patient interactions with a mobile 
device, the quality of data reported by patients using the 
mHeathApp, and data artificially classified using com-
plex software sensors (i.e., mood estimation, recognition 
of symptoms of depression). A detailed understanding 
of different individual, intervention and design factors 
that have the potential to alter quality of collected data is 
needed [20, 21].
Objectives and hypotheses
The objective is to determine if and how a mobile health 
system (mHealthApp), supported by data-driven Clinical 
Decision Support System (CDSS), both developed within 
the project PERSIST [22], will positively affect the behav-
ior of survivors of breast cancer and colorectal cancer. 
The PERSIST intervention is expected to increase survi-
vors’ self-efficacy and satisfaction with care as well as to 
reduce psychological stress for a better management of 
the consequences of cancer and its treatment. Interven-
tion should result in an improved health outcomes and 
well-being. It should also re-integrate survivors into the 
labor market faster. By delivering prediction models from 
Big Health Data and a tool to support decision-making, 
PERSIST will enable clinicians to make optimal treat-
ment decisions that have a positive impact on the survi-
vor’s quality of life and health. The improved information 
and evidence will increase the effectiveness in cancer 
treatment and follow-up, i.e. effectiveness of manage-
ment, intervention and prevention policies/strategies in 
order to respond quickly to the side effects and, if possi-
ble, avoid secondary diseases and fatal events, compared 
to regular routine. The long-term result is expected to 
reduce the socio-economic burden related to cancer sur-
vivors’ care.
The primary clinical objective is to assess the accept-
ability and usability of the mHealthApp and its impact 
on perceived self-efficacy and satisfaction with care 
from the perspective of the survivor. To evaluate the 
primary objective, two validated tools measuring self-
efficacy can be utilized, Communication and Attitudi-
nal Self-Efficacy scale for cancer (CASE-cancer) [23] 
and Strengths Self-Efficacy Scale (SSES) [24]. CASE-
cancer was chosen since self-efficacy has been shown to 
be a protective effect for survivors who have higher per-
ceived risk of recurrence [25–27]. Indivduals who are at 
higher risk with respect to health and well-being indi-
cators may benefit more from the digital intervention.
The secondary clinical objectives include meas-
uring the patient activation and acceptance of the 
mHealthApp and experience of its use among them. 
Patient activation represents the knowledge, skills, 
and confidence to manage one’s health. In multiple 
chronic conditions, it has been shown to contribute to 
improved self‐management behaviors [28, 29]. More 
active patients are more likely to believe their treat-
ment plans reflect their values, more likely to face side 
effects, and more likely to initiate a healthier diet after 
diagnosis than less active patients [30]. Less active 
patients are less likely to understand their diagnosis, 
follow treatment regimens, and be satisfied with their 
care. System Usability Scale (SUS) [31], and User Expe-
rience Questionnaire (UEQ) [32] will be used to assess 
acceptance, user experience and possible issues regard-
ing the use of mHealth App. Factors with significant 
impact on behavioral intention and motivation of use of 
mHealth Apps are perceived usefulness and ease of use, 
perceived risk and trust, the subjective norm and atti-
tude [33]. Perceived ease of use is especially significant 
factor for middle-aged and older survivors.
Finally, the secondary clinical objectives also include 
the evaluation of the effectiveness of health monitor-
ing and patient gathered health data (PGHD). PGHD 
includes self-reported health and treatment histories, 
patient-reported outcomes (PROs), and biometric data 
[34]. There is a growing interest in PGHD in oncol-
ogy. Namely, patient reported symptomatology tends to 
provide a significantly richer information source then 
Clinicians’ ratings of adverse events. Moreover, there is 
increasing evidence that integrating PGHD into clini-
cal care can improve outcomes over standard care [35]. 
Despite the abundance of opportunities, the uptake of 
digitals tools is surprisingly slow. The two major concerns 
are the interpretation and quality of data and the con-
cern that reliance on PGHD from wearable devices could 
exacerbate health disparities, especially in elderly and 
individuals with less-favorable socioeconomic situations 
[35–40]. Especially in PROs, the quality of self-reported 
data depends upon respondents’ ability and willingness 
to provide accurate and valid responses. Inattentive or 
careless is defined as an action in which respondents pro-
vide answers for the sake of the survey (i.e., a form of sur-
vey “satisficing”.) [40]. Thus the respondent does not fully 
read and/or interpret the question and fails to generate 
a meaningful response. To measure possible inattentive 
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and carless in responding, we will deploy the Directed 
Questions Scale—DQS [41].
Hypothesis
Performing a comparison between the beginning and 
the end of the intervention, participants will significantly 
increase their self-efficacy following the personalized 
intervention supported by the mHealthApp.
Primary and secondary endpoints
The primary endpoint is defined as: increased perceived 
self-efficacy in participants (80 colorectal, 80 breast can-
cer survivors from the 4 pilot hospitals) following the 
mHealthApp supported intervention as measured using 
CASE-cancer scale for cancer as the validated standard-
ized measure.
The secondary endpoints include:
• observing modifications in patient activation levels 
measured using the PAM,
• observing modification in User acceptance depend-
ing on the level of support measured via SUS and 
UEQ,
• description of negative outcomes over time: hospital-
ization, exacerbations, treatment adherence, depres-
sion, recurrence, drug escalation,
• impact of variable modes of delivery (e.g., conver-
sational agent) on quality of answers measure with 
DQS,
• the impact of patient trajectories (extracted from ret-
rospective data) and PGHD on prediction of possible 
secondary disease or negative outcome,
• the impact of patient trajectories (extracted from ret-
rospective data) and PGDH on improved interven-
tion against the appearance of secondary diseases, 
worsening late toxicities or development of fatal 
events (sudden death, suicide).
Methods/design
Study design
A single-case experimental prospective study was 
designed in alignment with single-case experimental 
design (SCED) methodology [42]. Within SCED, each 
individual is his/her own control group based on the first 
measurement prior to the intervention. The SCED was 
selected since single-case designs can capitalize on the 
ability of technology to easily, unobtrusively, and repeat-
edly assess health-related behavior [43]. The study design 
is highlighted in Fig. 1. It is based on the Changing Cri-
terion design in which the intervention and delivery of 
intervention are modified through personalization of (a) 
goals/tasks and (b) with spoken language interfaces and 
embodied conversational agents to complement the reg-
ular baseline delivery mode via the digital interfaces of 
the mHealthApp. The study will take place between 1st of 
May 2021 and 31st of December 2022, with the recruit-
ment period between 1st of April 2021 and 15th May 
2021. Data collection is first carried out prior to inter-
vention, during recruitment round (T1). Each recruited 
individual will sign a letter of consent and fill in CASE-
cancer and PAM questionnaires. The SUS questionnaire 
responses, along with CASE-Cancer and PAM will be 
collected following a baseline phase (T2) which will last 
for 6 months. During this phase a ‘generic’ intervention 
will include a recording of the diary (at least 3 times a 
week), report regarding their emotional state (at least 
once a day) and answering a specific PRO for report-
ing Health Related QoL and symptoms (a different PRO 
each day). In total, we expect 10–15  min of interaction 
every day. T2 will conclude with the first follow-up with 
clinician, during which data regarding primary (CASE-
Cancer, PAM, SUS/EUQ) and secondary endpoints will 
be collected. The personalized intervention phase (T3) 
will include execution of tasks on mHealth App personal-
ized for the survivor. The data collection tools will remain 
the same, however the responsible oncologist will define 
which of the tools the patient must implement (e.g., 
which PROs) and in what frequency, depending on the 
risk assessment implemented by the clinical staff. Dur-
ing intervention, specific tools may change depending on 
the risks detected for the specific patient. T3 concludes 
with a follow-up during which data regarding primary/
secondary endpoints (CASE-Cancer, PAM, SUS/UEQ). A 
first comparison between generic intervention and per-
sonalized intervention will be made. The AI supported 
clinical intervention (T4) will introduce embodied con-
versational agent EVA [44] and AI-drive risk assessment 
engine to deliver fully personalized intervention and 
to demonstrate that the data-driven models developed 
within PERSIST can improve quality of life of cancer sur-
vivors by acquiring, managing, sharing, and processing 
big data to create overall actionable insights at the point 
of care.
During the final follow-up, the data regarding the pri-
mary/secondary endpoints will be collected. To measure 
the overall impact of the digital intervention we will adapt 
the Model for the Assessment of Telemedicine (MAST) 
methodology [45]. The patient domain will be assessed 
through CASE-cancer, PAM, SUS, UEQ. The clinical rel-
evance will be assessed by: (i) analyzing the impact of Big 
Data prediction models to support decision-making in 
patient follow-up, and (ii) the impact of the intervention 
on against the appearance of secondary diseases, worsen-
ing late toxicities or development of fatal events (sudden 
death, suicide).
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Study setting
The study will involve 160 survivors (80 survivors of 
Breast Cancer and 80 survivors of Colorectal Cancer) 
from four countries, Belgium, Latvia, Slovenia, and Spain. 
Each of the sites will recruit 40 cancer survivors accord-
ing to the inclusion/exclusion criteria. Study will involve 
the use of digital intervention during every-day activi-
ties outside the clinical environment (i.e., at the subjects’ 
homes). The data collected will be evaluated during regu-
lar 6 month follow ups.
Study itinerary
Follow-up data will include updated information on main 
outcomes (acceptability and usability). Specific question-
naires related with satisfaction and usefulness will be 
applied to patients and physicians. In addition, healthy 
habits, disease knowledge, self-management, QoL, and 
morbidity and mortality end-points will be analyzed.
The recruited patients will receive the necessary 
devices for the correct development of the follow-up 
phase of the clinical study: a smartphone and a wearable 
quantifying device for physical activity estimation and 
health parameters measurement (such as blood pressure 
and heart rate). The overall Implementation of the study 
is visualized in Table 1.
Participants and recruitment
A 3-month period of recruitment is initially estimated, 
with 1 month of active enrolment. Before the enrolment, 
the first 2  months of the period will include a medical 
evaluation. This will confirm the curative cancer treat-
ment process and verify that the patient meets all inclu-
sion criteria but none of the exclusion ones. During 
recruitment, we will also provide further information 
about the study to eligible patients and give them the 
informative brochure and the informed consent form to 
sign.
Patient information and informed consent
Clinical partners will develop an informed consent docu-
ment translated in their local language and will apply 
for their local or national bioethics committee approval. 
GDPR regulation will be strictly followed to protect per-
sonal data of participants. Each center will be responsi-
ble to obtain a signed informed consent from the patient 
before inclusion in the study. The participants will be 














Overall impact of the digital intervention (MAST 
Methodology) 
Enrolment  
Fig. 1 The design of the single‑case experimental prospective study
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different EU countries (Belgium, Latvia, Slovenia and 
Spain). Every clinical partner will involve 40 survivors, 
20 patients from C18/C19 (Colorectal cancer) and 20 
patients from C50 (breast cancer). In total 160 patients 
will be recruited to participate in envisioned two-phases 
clinical study. The recruitment stage will begin in April, 
2021. The study will involve breast and colorectal cancer 
patients who have survived beyond curative cancer treat-
ment. We will consider a survivor patient all breast and 
colorectal cancer patients who survive without recur-
rence beyond 3–24  months after the end of treatment 
(surgery ± radiation therapy ± chemotherapy), they have 
received. For colorectal cancer survivors’ group, two 
subgroups will be included (chemotherapy and non-
chemotherapy). None of the groups will be lower than 
33% in ratio to the other. For breast cancer survivorspa-
tients that have had surgery and patients that have had 
chemotherapy.
Inclusion criteria
≥ 18 and ≤ 75  years at the moment of recruitment; sta-
ble clinical situation, life expectancy of more than 
2 years according to researcher opinion; ability to under-
stand study instructions, fulfil follow-up visits and sign 
informed consent; sufficient level of technology literacy 
enabling the patient to manage mobile terminals (smart-
phones, smartphone apps, tablets); good internet con-
nection in his/her place of residence or mobile data-plan.
Exclusion criteria
Life expectancy, under the physician opinion, of less than 
one year; diagnosis of dementia or cognitive decline that 
makes him/her unable to understand study information 
and/or sign informed consent; low capacity for self-man-
agement due to dependence on other person for medica-
tion compliance, or measuring blood pressure and daily 
weigh; lack of decision capacity in relation with diet or 
preparing meals; current participation in other clinical 
study; patient has no further follow-up possibilities with 
enrolling investigation during planned study period (such 
as anticipated relocation); patients with major depression 




The intervention will be delivered via mHealthApp and a 
smart band. The data related specifically to the primary 
and secondary end-point will be collected during regu-
lar follow-ups. During recruitment, patients will receive 
a smartphone the smart band and training materials. 
Demonstration workshops (at some hospitals) will be 
organized to showcase the use of the mHealthApp and 
resolve possible initial issues. During the intervention, 
technical support will be available to resolve any possible 
complications.
Possible HRQoL specific measures
General assessment (functioning and  self-efficacy) 
and recurrence All cancer survivors should be assessed 
at least once a year. The assessment should include symp-
toms related to cancer and symptoms prior to treatment. 
The appropriate follow-up care should be clinically indi-
cated. This assessment can be done by the oncologist or 
primary care clinician.
Depending on the cancer type and stage of disease, 
transition of care to primary care may be done when 
deemed clinically appropriate, with referral back to onco-
logic care as needed. It is not assumed all survivorship 
issues are addressed at every visit. Functioning and dis-
ability are concepts in increasing use in clinical settings 
and in public health and much related to cancer sur-
vivorship [46]. The use of functioning as a third health 
indicator could offer much more than the frequency of 
a disease and the survival rates. From the public health 
perspective, it reveals information on how the popula-
tion performs its activities and participation. Validated 
tools used to screen for long-term and late physical and 






Visit 2 (T2) Visit 3 (T3) Visit 4 (T4)
Informed consent X
Inclusion/exclusion criteria X
Questionnaires for Primary and Secondary 
endpoints
X X X X
Medical history (data collection) X
Candidate receives a smartwatch X
Candidate receives a smartphone X
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psychosocial effects of cancer and its treatment survivors 
already exists. WHODAS 2.0 [47] is a tool to for evaluat-
ing health and functioning based on the ICF functional 
model. It is an alternative to the ICF whose main criticism 
relates to the effort required to complete. It is 36-item 
self-administered questionnaire (or proxy-administered) 
regarding disability. The WHO-DAS II measures dis-
ability in 6 domains: understanding and communicating 
(cognitive), getting around (mobility), self-care, getting 
along with people, life activities (domestic responsibili-
ties, leisure, work), and participation in society. In addi-
tion to 36 item versions, there is also a 12-item version. 
It is useful for brief assessments of overall functioning in 
surveys [48].
The General Self-efficacy Scale (GSES) [49] is a vali-
dated self-report measure that assesses the overall 
impression of one’s ability to deal with demanding situa-
tions. GSES consists of 10 questions that require patients 
to self-evaluate, on a scale from 1 (not at all true) to 4 
(exactly true), statements regarding their confidence in 
dealing with unexpected events [50].
Regarding screening, breast cancer imaging with 
annual mammography and possibly magnetic resonance 
imaging (MRI) is suggested for women who have been 
treated with RT. For those not treated with RT, age-
appropriate screening guidelines should be followed. Fol-
lowing the NCCN2020 guidelines [37, 51] a PREM was 
designed as a screening tool focusing on breast cancer 
recurrence or new primary breast cancer. For survivors 
treated with RT to the abdomen, pelvis, spine, or trau-
matic brain injury, COG guidelines recommend surveil-
lance with colonoscopy from age 30, with further interval 
screening based on clinical findings at colonoscopy.
Assessment of  Health Related Quality of  Life 
(HRQoL) QoL represents a person’s perception on their 
position in life. It reflects the context of the culture and 
value system in relation to their goals, standards, and con-
cerns. In order to assess HRQoL the European Organiza-
tion for Research and Treatment of Cancer Core Cancer 
Quality of Life Questionnaire (EORTC QLQ-C30) [52] 
was selected as the relevant tool. The EORTC QLQ‐C30 
is a 30‐item cancer‐specific HRQoL instrument produc-
ing a global health status, five functioning scales (physi-
cal, role, social, emotional and cognitive functions), three 
symptom scales (fatigue, nausea/vomiting and pain) and 
six single‐symptom items (dyspnoea, insomnia, appetite 
loss, constipation, diarrhoea and financial difficulties), but 
no single‐index values.
Assessment of  cardiovascular risk Cancer treatments 
can result in diverse cardiovascular issues. NCCN2020 
guidelines [37, 51] focus specifically on heart failure 
or cardiomyopathy that may arise from anthracycline 
therapy. However, cardiomyopathy may be laso caused 
by other systemic therapies, i.e., HER2-targeted thera-
pies and other myopathies, i.e., myocarditis [53]. Signs 
of cardiac dysfunction can be observed even prior to the 
development of symptoms [37]. If detected early the car-
dioprotective medications can mitigate the anthracycline-
induced heart failure. However, there is only limited num-
ber of prospective studies evaluating these medications 
[37].
Assessment of  lymphedema Lymphedema, a side effect 
of cancer treatment, results from damage to the lymphatic 
system. It occurs on the same side of the body as the can-
cer treatment, when lymph fluid accumulates in the inter-
stitial tissue [37, 51]. This causes swelling of the limb or 
other areas such as the neck, trunk, or genitals. The diag-
nosis of lymphedema is, in most cases, confirmed within 
18  months of treatment; however, it can develop at any 
time in the survivor’s life [37, 51]. The cohort with higher 
risk of developing the lymphedema is represented by sur-
vivors that underwent surgery and/or radiation to the axil-
lary, supraclavicular, cervical, or inguinal lymph node sys-
tem [37, 51, 54]. Since stages 0 and 1 are reversible, early 
diagnosis is the key to optimal treatment. The stages 2 and 
3, however, are less responsive to treatment. The prospec-
tive surveillance model (PSM) had been recognized as an 
optimal framework to guide clinical implementation of a 
screening methodology for early identification and man-
agement of breast cancer treatment-related impairments 
[55]. PSM can help in early identification and treatment 
of lymphedema, even in subclinical stage. In the subclini-
cal stage, the intervention can prevent the progression to 
a more chronic form. According to NCCN2020 guide-
lines, survivors with high risk; i.e. a history of radiation or 
surgery to the lymph nodes, should be questioned about 
swelling or feeling of heaviness, fatigue, or fullness at each 
visit [37, 51].
Assessment of  pain Over one-third of post-treatment 
cancer survivors experience chronic pain. It often leads to 
psychological distress; decreased activity, motivation, and 
personal interactions; and an overall poor quality of life 
[56]. In general pain can be nociceptive or neuropathic. 
Somatic nociceptive pain is described as sharp, throb-
bing, or pressure-like. It often occurs after surgical pro-
cedures. The visceral nociceptive pain is often diffuse and 
described as aching or cramping [56]. Neuropathic pain 
is a result of an injury to the peripheral nervous system 
or CNS and might be described as numbness or as burn-
ing, sharp, tingling, prickling, electrical, or shooting pain. 
Often it develops as a side effect of chemotherapy or radi-
ation therapy or is caused by surgical injury to the nerves. 
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For this reason, it is very common among breast and colo-
rectal cancer survivors. Unfortunately, there is few data 
on effective pharmacological treatments of CIPN.
The NCCN2020 guidelines [37, 51] make recommen-
dations to manage the following seven categories of 
pain: neuropathic, chronic, myalgias/arthralgias, skel-
etal, myofascial pain, gastrointestinal/urinary/pelvic 
pain, and post-radiation pain [37]. It, however, does not 
include The recommendations regarding prevention and 
management of chemotherapy-induced peripheral neu-
ropathy (CIPN). The recommendations for CIPN can be 
found in ASCO’s clinical practice guidelines [57]. Addi-
tionally, ASCO provides clinical practice guidelines for 
the management of chronic pain in adult cancer survi-
vors [58]. In PERSIST the Wong-Baker FACES Pain Rat-
ing Scale [59]. It is a unidimensional intensity scale and 
includes the 11-point numeric rating scale from 0 (no 
pain) to 10 (extreme pain) accompanied with visual/word 
descriptors.
Assessment of  hormonal imbalances The NCCN2020 
guidelines [51] define menopause as: (i) no menses for 
one year in the absence of prior chemotherapy or tamox-
ifen use or (ii) no menses after surgical removal of all 
ovarian tissue [37]. However, significant number of can-
cer survivors experience menopausal symptoms without 
meeting the above criteria. In fact, hormonal symptoms 
in cancer survivors have been most extensively studied in 
female survivors after treatment of breast cancer. Studies 
report that hot flashes, vaginal dryness and dyspareunia 
are common among breast cancer survivors [60]. Other 
symptoms of hormonal imbalance may be sexual dysfunc-
tion, depression, fatigue, etc. [37] From the NCCN2020 
guidelines [51] we select questions targeting vaginal dry-
ness, and urogenital complaints associated with meno-
pause when designing the specific PREM. Other symp-
toms are already addressed in other measures.
Assessment of sexual dysfunctions Sexual dysfunction is 
often caused by hormonal therapy and surgical or radia-
tion therapy directed towards the pelvis (i.e. during colo-
rectal cancer treatment) [37]. Depression and anxiety are 
commonly associated with survivorship and can further 
contribute to imparied sexual function [51]. Sexual dys-
functions after cancer treatment are more common in 
female survivors [61]. The female dysfunctions relate to 
issues with desire, arousal, orgasm, and pain. The prob-
lems vary depending on the cancer site and treatment 
modalities used. A prevalence of chemotherapy-induced 
menopause had been observed within the cohort of breast 
cancer survivors that were treated using chemotherapy 
[37]. Furthermore, body image changes related to breast 
cancer surgery and reconstruction can affect women’s 
sexual life and well-being [62].
Although effective strategies for treating both female 
and male sexual dysfunctions exists, sexual function is 
rarely discussed with survivors. In line with NCCN2020 
guidelines [51] and EORTC QLQ-BR45 [63] we designed 
a 2-question PREM as a screening tool.
Assessment of fatigue In order to promptly diagnose and 
effectively treat moderate and severe fatigue, all survivors 
should be screened for symptoms of fatigue [37]. Fatigue 
is a highly subjective experience. In order to include 
fatigue in clinical routine the clinicians must understannd 
patients’ interpretations of their fatigue level. To stand-
ardize the patient reports NCCN guideliness propose to 
evaluate the fatigue through three and one item severity 
scales [64].
Assessment of  symptoms of  anxiety Fear of recurrence, 
distress, anxiety and depression are the most relevant 
mental health risks for cancer survivors. These risks may 
persist many years after diagnosis. The NCCN Guidelines 
provide a questionary for patient self-assessment and an 
algorithm for oncologists and other health care providers 
to screen for distress, anxiety, and depression in cancer 
survivors. The algorithm focuses on common mood dis-
orders after cancer and is not intended as a psychiatric 
diagnosis tool [37]. For PERSIST the Generalized Anxi-
ety Disorder (GAD-7) [65] questionnaire was chosen to 
assess symptoms of anxiety. It is a validated diagnosis 
tool implemented as a 7-item, self-report questionnaire 
designed to assess the patient’s status during the previous 
2 weeks. The items target feelings of nervousness, anxi-
ety, or if the patient was on edge, not being able to stop 
or control worrying or over-worry different things. It also 
measures if the patient had trouble relaxing or if patients 
were easily annoyed or irritable and or afraid.
Assessment of  symptoms of  depression Symptoms of 
depression are pervasive in survivors. However, often the 
distressed survivors may not appear distressed. There-
fore, all survivors should be screened for anxiety, depres-
sion, and distress, especially at times of disease transi-
tion, surveillance, significant loss, major life events, and 
social isolation [37]. In fact, routine screening of cancer-
related distress, including clinical anxiety or depression 
and post-traumatic stress, should be carried out as part 
of the standard follow-up of survivors at least annually. 
Survivors with multiple or repeated somatic complaints 
should also be screened as part of their overall workup. 
However, the NCCN guidelines do not address how to 
detect somatic behaviors.
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Patient Health Questionnaire PHQ-9 [66] and Patient 
Health Questionnaire PHQ-2 [67] were chosen as screen-
ing tools. The PHQ-9 is the 9-item depression module. 
Major depression is suspected if, in the past 2  weeks, 
five or more of the nine criteria have been observed at 
least “more than half of the days”. Additionally, one of 
the symptoms is depressed mood or anhedonia [68]:2. 
The PHQ-2 is a short version. It uses the first 2 questions 
of the PHQ-9 to investigate the frequency of the symp-
toms of depressed mood and anhedonia. Each question is 
scored as 0 (not at all) to 3 (nearly every day).
Assessment of  cognitive function The hypothesis that 
neurotoxicity resulting in brain white matter damage 
plays an important role in cognitive deficits after chem-
otherapy had been supported by multiple studies [69]. 
Functional MRI studies show that changes in brain activ-
ity accompany cognitive complaints or cognitive deficits 
in survivors [70]. In line with NCCN2020 guidelines [37, 
51] and EORTC QLQ-BR45 [62], we designed a 3-ques-
tion PREM as a screening tool. Further, as a more in-
depth tool FACT-Cog [71] can be used to further assess 
cognitive complaints in cancer patients. FACT-Cog is a 
37-item questionnaire. It measures complaints in six cog-
nitive domains: memory, concentration, mental acuity, 
verbal fluency, functional interference, and multitasking 
ability. Moreover, the tool includes two other subscales: 
‘‘comments from others’’ (i.e. ‘‘noticeability’’) and ‘‘effect of 
perceived cognitive impairment on quality of life’’.
Assessment of  healthy lifestyle, nutrition and  physical 
activity Cancer survivors are often motivated towards 
self-intervention to improve their treatment outcomes, 
QoL, and overall survival [72]. They often seek informa-
tion about dietary options and supplements, and physical 
activity. Namely, all cancer treatments (i.e., surgery, radia-
tion, and chemotherapy) can significantly affect nutri-
tional habits, alter regular eating patterns, and adversely 
affect how the body digests, absorbs and uses food. Fol-
lowing NCCN2020 guidelines [51], we designed a PREM 
for nutritional assessment. It comprises of questions 
assessing (healthy) nutrients and fluids intake, weight var-
iation, meal frequency, and eating habits.
Further, Physical activity represents an appealing inter-
vention. It could alleviate sequelae related to cancer and 
assist patients in returning to the health status they had 
before treatment [73]. It has positive effects in physiol-
ogy, body composition, physical functions, psychological 
outcomes, and quality of life in patients after treatment 
for breast cancer [73]. To assess physical activity the 
Global Physical Activity Questionnaire (GPAQ) [74] 
was chosen as the appropriate tool. GPAQ measures the 
number of minutes spent in three areas, work, leisure, 
and transportation in a typical week, i.e., spent for walk-
ing/cycling to get to and from locations. Using this data 
GPAQ calculates metabolic equivalents to express the 
intensity of self-reported physical activities.
Data collection
Baseline data to be collected during or right after recruit-
ment (T1): clinical and demographic data as well as social 
aspects of health status and QoL (social determinants 
of health). During recruitment baselines, data regarding 
survivor’s activation (PAM) and self-efficacy (CASE-Can-
cer) will be collected.
Data collection will be provided by Smart devices LZD 
Smart band (Fitbit like) from Naicoms and Smartphone. 
This data includes:
• data reported by patients using the mobile applica-
tion – based on PROs: we will deliver and select form 
the following tools: Quality of life for cancer patients 
(EORTC QLQ‐C30), Patient Health Questionnaire-2 
(PHQ-2), Patient Health Questionnaire-9 (PHQ-9), 
General Anxiety disorder (GAD-7), WHO Disabil-
ity Assessment Schedule (WHODAS 2.0), proprie-
tary questionnaires were designed by participating 
oncologists for additional risk assessment related to 
health-related specific symptoms related to physical 
symptoms, cardiovascular risks, pain, fatigue, malnu-
trition, lymphedema, hormonal disbalances, sexual 
dysfunction, gastrointestinal conditions and cogni-
tive functioning.
• data from the physical activity tracker worn by the 
patient: Vital signs and physical activity. Blood pres-
sure, heart rate, Blood Oxygen, Steps, Calories, Dis-
tance, Running Track, Sleep Monitor—built in the 
firmware of the watch.
• data from software sensors to be developed by UM 
and SYM (e.g., facial action units, acoustic features, 
emotion and mood estimation extracted from diary 
recordings).
The pseudo-anonymised data will be stored in a Big 
Data platform hosted in CESGA infrastructures (CESGA 
is a Spanish public institution offering high performance 
computing services for administrations and research 
purposes).
The data is gathered in the following way:
• Manually (T2 and T3)—obtain patient information 
using questionnaires (PROMs, PREMs and health-
related questions) displayed in a Smartphone screen.
• Supported (T4)—the component will converse with 
the users using natural free speech. It will be able to 
engage with them in an organic dialogue by helping 
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the user to provide answers to PROs and to health-
related questions.
• Automated Classification (T2, T3 and T4): Speech 
recognition and feature extraction from recorded 
interaction. Facial biomarkers will be used to extract 
facial action points. Speech biomarkers will be used 
to extract acoustic features from the interaction. Text 
features (i.e., words, sentiment, syntax and seman-
tics, topic and named entity classification and mor-
phology) will be extracted from recognized speech.
Outcomes (CASE‑Cancer, PAM, SUS/EUQ)
The outcomes of this clinical study will be measured and 
evaluated using CASE-Cancer, PAM, SUS and EUQ. First 
questionnaire battery (T1) will include CASE-Cancer 
and PAM, and will be administered in all four batteries 
(T1–T4) to establish the patients’ baselines. All succes-
sive batteries (T2, T3, and T4) will include two additional 
questionnaires.
The four questionnaire batteries (pre-screening, T1, 
T2, T3) measure primary outcomes. In the pre-screening 
questionnaire, additional questions aimed at collecting 
data on background variables (e.g., demographic data) 
are foreseen. The questionnaire battery administered at 
T1, T2, and T3, will also include the patent activation 
measure. Additional background variables, such as over-
all satisfaction with the intervention and satisfaction with 
the system will be assessed at T2 and T3 (directly after 
the intervention, e.g.,).
Statistical analysis
Despite this is mainly a pilot study of acceptability, usa-
bility and analysis of surrogate variables, sample size is 
estimated according to expected effectiveness in chang-
ing healthy habits in patients. This is based on previous 
peer-review published studies with mobile devices in 
cancer survivors.
An article by Pope et  al. [75] investigated the impact 
and feasibility of commercial mobile health applica-
tions and social media to improve physical activity and 
health of breast cancer survivors. They provided a digi-
tal health education intervention to breast cancer survi-
vors. The results show positive post intervention trends 
in increased average daily moderate-to-vigorous physi-
cal activity and steps. The results of the study show 
a notable decrease in weight (2.4  kg) and body fat per-
centage (2.3%). Quintiliani et  al. [76] aimed to evalu-
ate engagement (use and acceptability), physiological 
(weight), behavioral (diet and physical activity), and 
other secondary outcomes among Breast Cancer Sur-
vivors. The engagement was high: the mean number 
of days recording steps via the wristband pedometer, 
recording a weight via scale, and responding to text mes-
sages was high, and 100% of participants completed all 
4 calls with the counselor. The mean weight of partici-
pants decreased. The daily intake of fruit and vegetables 
increased, and self-reported moderate physical activity, 
measured in metabolic equivalent of task (MET) minutes 
per week, increased [76]. Most of the participants would 
very likely participate again and would recommend the 
app to others.
Sample size calculation
To estimate the sample size to difference between two 
dependent means we have based on the assumptions of 
a two-sided confidence level of 95%, a statistical power 
of 90% and effect size Cohen’s d of 0.25. The previous 
assumptions indicate that 160 patients may detect differ-
ences between pre and post variables of healthy habits. A 
G*Power 3.1 software was used to make this sample size 
estimation.
Statistical analysis
A descriptive analysis of clinical characteristics will be 
performed. The quantitative parameters will be summa-
rized by its average ± standard deviation and percentiles, 
while for the qualitative variables the frequencies and 
percentages will be computed correspondingly.
In order to test the objectives, for CASE-cancer, SUS/
UEQ and scores as well as for single items, differences 
between pre, post, and follow-up measurements will be 
analyzed by parametric test (Student’s t-test/ANOVA), 
non-parametric test (Wilcoxon signed-rank test) and 
McNemar test (for categorical measures).
Descriptive statistics of the negative outcomes and/or 
complications (hospitalization, exacerbations, treatment 
adherence, depression, reoccurrence and drug escala-
tion) reported in the study will be used. These measures 
and patient trajectories (appearance of secondary dis-
eases, worsening late toxicities or development of fatal 
events) will compare with data extracted from retrospec-
tive study. We will use univariate tests like Student’s t-test 
and chi-square test and multivariate models. For all the 
comparisons, sub-analyses will be carried out stratifying 
by type of cancer, sex and any other variable considered 
of interest.
An intention-to-treat analysis and sensitivity analysis of 
observed data will be performed. We will use R 3.4.2 and 
SPSS version 19 for statistical analysis. Test results with a 
p value below 0.05 will be deemed statistically significant.
Discussion
Cancer survivors have complex needs that must be fully 
recognized and addressed in a comprehensive and coordi-
nated manner. In the last decades, evidence is emerging that 
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lifestyle of cancer survivors positively influence cancer prog-
nosis as for example exercise, increased fruit and vegetable 
consumption, healthy body weight and body composition, 
smoking cessation, and cognitive behavioral therapy. How-
ever, few survivors can meet all of these recommendations. 
According to the “European Guide on Quality Improve-
ment in Comprehensive Cancer Control” [77], “follow-up, 
late effect management and tertiary prevention need to be 
anticipated, personalized and implemented into care path-
ways, with the active participation of survivors and relatives.” 
This study also concludes that “no clear consensus exists on 
follow-up care plans for survivors” and that “more research 
in survivorship is needed. The research needs to provide data 
on late effects, and data on impact and cost-effectiveness of 
supportive care, rehabilitation, palliative and psychosocial 
care interventions” [77]. The global challenge is to provide 
evidence base and tools for the development of policy strat-
egies to improve the delivery of cancer survivorship care 
and the QoL after the cancer treatment (including preven-
tion, early diagnosis, therapies as well as addressing health 
inequalities). The proposed clinical study targets a demand 
towards a more patient-centered cancer survivorship care 
to increase awareness and self-efficacy (engagement in their 
care plans). To address this demand a mHealth App capable 
of collecting PGHD and PROs is delivered and evaluated. 
Often survivors remain unaware of their risk of recurrence 
and late effects and have no holistic plan for follow-up care. 
This study is expected to highlight the main benefits of digi-
tal interventions (Big Data, Artificial Intelligence and Digital 
Sensing) as:
• increased self-efficacy and satisfaction with care and 
reduced psychological distress regarding manage-
ment of side effects or outcomes of treatment and the 
disease itself. This will result in an improvement in 
health and well-being and a faster integration in the 
labor market, where applicable, compared to usual 
care;
• increased effectiveness of cancer treatment and fol-
low-up routine supported by Big Data based knowl-
edge models. The models will support decision-mak-
ing and contribute to optimal treatment decisions. 
This will have direct impact on the QoL and the 
health status of survivors;
• improved patient context (i.e. information) and evi-
dence to improve the efficacy of management, inter-
vention and prevention policies/strategies, all target-
ing timely mitigation of side effects and, if possible, 
avoidance of secondary diseases and fatal events. The 
long-term result are foreseen to reduce the socio-
economic burden related to cancer survivors’ care.
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